The Board of Directors of BICO Group AB (publ) ("BICO" or the “Company”) has exercised the authorization granted by the Annual General Meeting to issue up to 6,408,626 class B shares (“New Shares”) in full, equivalent to ten percent (10%) of outstanding shares in the company prior to the transaction, through a directed share issue (the “Share Issue”) to Sartorius AG ("Sartorius"). The subscription price of the Share Issue amounts to SEK 76.00 (the “Subscription Price”), equivalent to a premium of 2.7 percent compared to the volume weighted average price of the last three (3) trading days for BICO’s class B shares on Nasdaq Stockholm preceding 8 December (the “3-day VWAP”). Through the Share Issue the Company will receive gross proceeds of approximately SEK 487m, before transaction costs, and will upon settlement result in an ownership for Sartorius of approximately 9.1 percent of the shares and 7.6 percent of the voting rights in BICO, following the transaction. Added to Sartorius' already existing holding in BICO, the total ownership amounts to approximately 10.1 percent of the shares and 8.5 percent of the voting rights.

In conjunction with the Share Issue, BICO and Sartorius have agreed on a comprehensive technology as well as sales and marketing cooperation. As part of the partnership, both companies will enter into a research & development collaboration relating to 3D cell printing and associated technologies as well as digital solutions for cell line development workflows. Additionally, it was agreed that Sartorius will become a distributor of BICO products in the Asia-Pacific (APAC) region.

“The strategic collaboration with Sartorius is expected to significantly expand our presence and accelerate growth in Asia-Pacific, where BICO today has considerable expansion potential. BICO will get access to value adding, complementary technologies and products, which will enhance our current customer offering within bioprinting and lab automation. We consider the Sartorius ownership in BICO as a verification of the BICO growth strategy,” says Erik Gatenholm, CEO and co-founder of BICO.

“The cooperation with BICO will enable us to jointly strengthen our activities in very dynamic fields like advanced cell models and digital workflows in drug research and development. We will further enhance the position of both companies in the fast-growing Asian markets with highly differentiating and relevant technologies. We are convinced that the strategic partnership and the investment in BICO will create value for both parties,” says Gerry Mackay, member of the Executive Board and Head of the Lab Products & Services Division of Sartorius.
 
About Sartorius
Headquartered in Göttingen, Germany, the Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry and listed on the Frankfurt Stock Exchange, with a market capitalization of approximately EUR 23 billion. The company has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2021, Sartorius earned sales revenue of some 3.45 billion euros. At the end of 2021, nearly 14,000 people were employed at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.

With innovative laboratory instruments and consumables, the Group’s Lab Products & Services division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently.
 
The Share Issue
The Share Issue in brief:

• The Share Issue consists of a total of 6,408,626 New Shares to Sartorius, resolved by the Board of Directors based on the authorization granted by the Annual General Meeting on 26 April 2022.
• The subscription price per New Share amounts to SEK 76.00 and has been determined by the Board of Directors of the Company following arm’s-length negotiations with Sartorius. The subscription price is equivalent to a premium of 2.7 percent compared to the 3-day VWAP of approximately SEK 74.02.
• Through the Share Issue, the Company will receive gross proceeds of approximately SEK 487m, before transaction costs.
• The Share Issue will result in a dilution of approximately 9.1 percent of the number of shares and approximately 7.6 percent of the number of the voting rights in BICO. Through the Share Issue, the number of shares in the Company will increase by 6,408,626 to 70,494,895 and the number of voting rights will increase by 6,408,626 to 83,994,895 shares in total, divided between 1,500,000 A shares and 68,994,895 B shares following the Share Issue. The share capital will increase by approximately SEK 160,215.65 from approximately SEK 1,602,156.725 to approximately SEK 1,762,372.375.
• Upon settlement the transaction will result in an ownership for Sartorius of approximately 9.1 percent of the shares and 7.6 percent of the voting rights in BICO. Added to Sartorius' already existing holding in BICO, the total ownership amounts to approximately 10.1 percent of the shares and 8.5 percent of the voting rights. 

Background of the strategic cooperation
In conjunction with the Share Issue, BICO and Sartorius have agreed on a comprehensive technology as well as sales and marketing cooperation. As part of the partnership, both companies will enter into a research & development collaboration relating to 3D cell printing and associated technologies as well as digital solutions for cell line development workflows. Additionally, it was agreed that Sartorius will become a distributor of BICO products in the Asia-Pacific (APAC) region. The cooperation will be based on mutually commercially attractive terms and on arm's-length principles.
 
Deviation from the shareholders’ preferential right
The Share Issue is intended to be carried out with deviation from the shareholders’ preferential right. In relation to this, Company’s Board of Directors has made an overall assessment and carefully considered alternatives for strengthening its financial position through a capital increase and has concluded that a directed share issue is in the best interest for the Company and its shareholders. The Board of Directors has concluded that reasons supportive to the Share Issue are, among other things:

• the Share Issue is conducted at a premium, with the Subscription Price equivalent to a 2.7 percent premium compared to the 3-day VWAP,
• the Share Issue will provide the Company with a significant and reputable long-term shareholder in Sartorius,
• the technology as well as sales and marketing cooperation with Sartorius in conjunction with the Share Issue entails several commercial and strategic benefits for BICO,
• the Share Issue can be conducted in a more time efficient way and at a lower cost and with less complexity for the Company than through a rights issue,
• a strengthening of the Company’s financial position will enable the Company to more swiftly executing on strategic initiatives, and
• the overall importance of a strong balance sheet when navigating in the current market environment.

Use of proceeds
BICO intends to use the net proceeds received from the Share Issue to strengthen the Company’s financial position, to accelerate the Company’s growth agenda and further cement its already well-established market position.
 
Advisors
Carnegie Investment Bank AB acts as Sole Global Coordinator and Bookrunner and Advokatfirman Vinge KB acts as legal adviser to BICO in connection with the Share Issue.